APA (7th ed.) Citation

Tanaka, T., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., . . . Kumada, T. (2022). Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice. Hepatology research, 52(9), 773-783. https://doi.org/10.1111/hepr.13797

Chicago Style (17th ed.) Citation

Tanaka, Takaaki, et al. "Therapeutic Efficacy of Atezolizumab Plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma in Patients with Child‐Pugh Class A or B Liver Function in Real‐world Clinical Practice." Hepatology Research 52, no. 9 (2022): 773-783. https://doi.org/10.1111/hepr.13797.

MLA (9th ed.) Citation

Tanaka, Takaaki, et al. "Therapeutic Efficacy of Atezolizumab Plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma in Patients with Child‐Pugh Class A or B Liver Function in Real‐world Clinical Practice." Hepatology Research, vol. 52, no. 9, 2022, pp. 773-783, https://doi.org/10.1111/hepr.13797.